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Abstract: 
The goal of this study was to determine whether extracts and isolated alkylamides 
from Echinacea purpureawould be useful for prevention of the inflammatory response that 
accompanies infections with H1N1 influenza A. Seventeen extracts and 4 alkylamides were 
tested for the ability to inhibit production of cytokines, chemokines, and PGE2 from RAW 264.7 
macrophage-like cells infected with the H1N1 influenza A strain PR/8/34. The alkylamides 
undeca-2Z,4E-diene-8,10-diynic acid isobutylamide, dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 
isobutylamide, dodeca-2E,4E-dienoic acid isobutylamide, and undeca-2E-ene-8,10-diynoic acid 
isobutylamide suppressed production of TNF-α and PGE2 from infected cells. Dodeca-2E,4E-
dienoic acid isobutylamide was especially effective at inhibiting production of these mediators 
and also strongly inhibited production of G-CSF, CCL2/MCP-1, CCL3/MIP-1α and 
CCL5/RANTES. In contrast, the ethanol extracts (75%), which were prepared from dormant 
roots of E. purpurea grown in different locations throughout North Carolina, displayed a range 
of effects from suppression to stimulation of mediator production. Precipitation of the extracts 
with ethanol removed the stimulatory activity, however, even after precipitation; many of the 
extracts did not display any suppressive activity. Analysis of the extracts revealed slight 
variations in concentration of alkylamides, caftaric acid, and cichoric acid, but the activity of the 
extracts did not strongly correlate with concentrations of these compounds. Our in vitro 
experiments suggest that E. purpurea extracts have the potential for use in alleviating the 
symptoms and pathology associated with infections with influenza A; however, further study 
will be necessary to define procedures necessary to unmask the alkylamide activity in crude 
extracts. 




According to figures reported in the Nutrition Business Journal, sales of Echinacea products in 
the US gross $120 million annually [1]. Echinacea is also widely used outside the US, for 
example, physicians in Germany write over 3 million prescriptions for Echinacea products each 
year [2]. Echinacea preparations, primarilyEchinacea purpurea, Echinacea angustifolia, and E. 
pallida, are employed for the treatment of upper respiratory infections. However, there is still a 
lack of agreement in the scientific community as to their effectiveness for this purpose, and 
clinical trials have yielded conflicting results [3], [4], [5] and [6]. Part of this confusion arises 
because Echinacea is typically used in the form of a crude extract or pill made from powdered 
plant material. Such preparations are inherently complex and variable in composition. While 
some of the Echinacea extracts used for therapeutic purposes are standardized to particular 
constituent levels, there is no consensus in the US dietary supplements industry as to which 
constituents should be used. This is not surprising given that there is still disagreement in the 
scientific community as to which constituents from Echinacea are responsible for its purported 
usefulness against upper respiratory infections, and how these constituents act. This lack of 
knowledge prevents effective quality control of Echinacea and limits the ability to conduct 
successful clinical trials. 
E. purpurea is the most commonly used and studied species of Echinacea, and is the subject of 
the studies described herein. The types of E. purpurea preparations that are most often employed 
therapeutically include ethanol extracts (which typically contain approximately 60% ethanol) [7], 
and aqueous extracts or “fresh pressed juice,” which are prepared without ethanol, but are 
typically preserved with a lower percentage of ethanol (in the range of 20%) [8]. The composition 
of complex Echinacea extracts varies depending on processing techniques and plant material 
used. It is generally assumed that ethanol extracts contain higher levels of alkylamides and 
phenolic compounds, while aqueous extracts are more likely to contain hydrophilic compounds 
such as polysaccharides and glycoproteins [9]. 
The current general consensus in the field of Echinacea research is that Echinacea preparations 
can have either stimulatory or suppressive effects on innate immunity depending on the nature of 
the preparation used.Echinacea fresh pressed juice [10] as well as crude 
ground Echinacea root [11] and [12], appears to enhance immunity by increasing production of 
certain cytokines from macrophages and monocytes. It is often suggested that this stimulatory 
effect may aid the body in warding off infection [13], and perhaps be helpful for preventing colds 
and flu. Polysaccharides [14], [15], [16] and [17] and/or lipopolysaccharides and 
lipoproteins [18] and [19] present in these Echinacea extracts may be responsible for their 
immunostimulatory activity. These compounds may come not just from the Echinacea plant 
itself, but from bacteria that are either introduced into the preparation as contamination or live in 
the plant as endophytes[18]. 
There is a growing community of scientists that attributes the usefulness of 
ethanolic Echinaceapreparations for treating infection to their ability to suppress the 
inflammatory response, thereby suppressing symptoms associated with the infection [20] and [21]. 
This activity is generally attributed to alkylamides and/or caffeic acid derivatives that are present 
at high levels in ethanolic extracts [13]. It is notable that such anti-inflammatory activity would 
constitute a “suppression” of innate immunity, as opposed to the immune enhancement that has 
typically been attributed to aqueous extracts of Echinacea. Sharma et al. [22] have shown that 
Echinforce®, a standardized ethanol extract prepared from fresh E. purpurea roots, can suppress 
cytokine and chemokine production from human blood monocytes stimulated by respiratory 
viruses. Furthermore, a number of studies with ethanolic Echinacea extracts or alkylamides 
from Echinaceapreparations have shown that they can inhibit the LPS-induced production of 
TNF-α, IL-1, IL-6, and IL-8 cytokines and chemokines from human monocytes/macrophages 
and from macrophage-like cell lines [23],[24], [25] and [26]. The alkylamides appear to mediate these 
effects through both cannabinoid receptor (CB)-dependent and CB-independent 
mechanisms [24] and [26]. 
In this investigation, we focused on the virus influenza A. Over 30,000 Americans die annually 
from infections with influenza A, and new treatments are clearly necessary. Many of the 
symptoms and pathology associated with this disease, including; fever [27], anorexia [28], nasal 
discharge [29], and pain [30] are dependent on the production of a “storm” of cytokines, 
chemokines, and inflammatory lipids. Given the previous studies suggesting anti-inflammatory 
activity of alkylamides from Echinacea, it is reasonable to hypothesize that the purported relief 
provided by Echinacea for influenza may stem from the ability of these compounds to suppress 
production of inflammatory mediators from virus infected macrophages. The goal of our studies 
was to evaluate the effects of alkylamides and alkylamide-containing E. purpurea extracts from 
diverse geographical locations on the production of inflammatory cytokines, chemokines, and 
lipids from influenza A-infected RAW 264.7 macrophages. Our overall objectives in conducting 
these experiments were to gain insight into the mode of anti-inflammatory activity of 
alkylamides from E. purpurea and to determine whether these compounds serve as useful 
biomarkers for the in vitro anti-inflammatory activity of complexE. purpurea extracts. 
2. Methods 
2.1. Plant material and standards 
Dormant E. purpurea roots were harvested from 17 cultivation sites across North Carolina 
between February and May 2008. Sites ranged from commercial farm fields to private gardens. 
Sites were selected to provide a wide representation of soils, climates, altitudes, and general 
growing conditions. In many cases, original seed sources were unknown. Plant ages varied from 
approximately 2 to 10 years at time of harvest. Roots were dug, washed, and dried at 38 °C under 
positive air flow. Voucher specimens for each harvest location were pressed, dried, and 
deposited in the University of North Carolina Herbarium (CB# 3280, Coker Hall, University of 
North Carolina, Chapel Hill, NC 27599-3280). Accession numbers correspond to the sample 
numbers listed in Table 1 as follows: sample 1 — NCU585854, sample 2 — NCU585842, 
sample 3 — NCU585843, sample 4 — NCU585858, sample 5 — NCU585848, sample 6 — 
NCU585859, sample 7 — NCU585851, sample 8 — NCU585849, sample 9 — NCU585860, 
sample 10 — NCU585852, sample 11 — NCU585846, sample 12 — NCU585853, sample 13 — 
NCU585856, sample 14 — NCU585857, sample 15 — NCU585844, sample 16 — NCU585845, 
and sample 17 — NCU585847. 
Table 1. Concentrations of the most abundant alkylamide, 11a/b (dodecatetraenoic acid 
isobutylamide) and caffeic acid derivatives (caftaric acid and cichoric acid) present in the ethanol 
precipitated extracts (85% ethanol) after dilution into the assay well. The same dilution was 
employed for all extracts, and original extract concentrations of extracts (prior to dilution into 
sample wells) are 172 times higher. For example, the extract concentration for dodecatetraenoic 
acid isobutylamide in sample 01 prior to dilution was 3.8 mM (0.9 mg/mL). Sample 7 displayed 
the most pronounced anti-inflammatory activity ( Fig. 6). 







μM μg/mL μM μg/mL μM μg/mL 
01 22.0 5.4 2.9 0.16 2.9 0.24 
02 11.0 2.7 4.1 0.22 4.6 0.38 
03 16.8 4.2 2.9 0.16 3.5 0.28 
04 16.2 4.0 3.5 0.19 3.5 0.28 
05 13.3 3.3 3.5 0.19 1.7 0.14 
06 9.3 2.3 7.5 0.41 12.2 1.00 
07 22.0 5.4 3.5 0.19 2.9 0.24 
08 11.6 2.9 5.2 0.28 4.1 0.33 
09 10.4 2.6 2.9 0.16 2.9 0.24 
10 9.3 2.3 4.1 0.22 2.3 0.19 
11 5.2 1.3 2.9 0.16 2.3 0.19 
12 4.6 1.1 2.3 0.12 2.3 0.19 
13 14.5 3.6 2.9 0.16 2.9 0.24 
14 11.0 2.7 4.6 0.25 7.0 0.57 
15 20.3 5.0 3.5 0.19 7.0 0.57 
16 10.4 2.6 7.5 0.41 8.7 0.71 
17 17.4 4.3 3.5 0.19 7.0 0.57 
 
Standards for alkylamides 4 (undeca-2E,4Z-diene-8,10-diynoic acid isobutylamide), 11a/b 
(dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide) and 15 (dodeca-2E,4E-dienoic acid 
isobutylamide) were obtained from Gaia Herbs (Brevard, NC, USA) and were identified based 
on retention time comparison and MS–MS fragmentation according to published 
literature [31], [32] and [33]. Standards for alkylamide 16 (undeca-2E-ene-8,10-diynoic acid 
isobutylamide) and the caffeic acid derivatives cafteric acid and cichoric acid were purchased 
from Chromadex (Santa Ana, CA, USA) with certificate of analysis indicating correct 
identification. Stock solutions were prepared from the standards in ethanol to produce final 
concentrations of 0.1,10, 50, 100, and 500 μM. 
2.2. Extraction 
Samples of dried E. purpurea roots were extracted within three weeks of drying. The whole 
dried roots were cut, and pulverized into a fine powder using a blender. The powder was 
macerated for seven days in 75% ethanol (Pharmaco-AAPER, Shelbyville, KY, USA) at a ratio 
of 1:5 (g plant material:mL solvent). The resulting extract was pressed using a hydraulic press 
and filter-sterilized through a 0.2 μM membrane under vacuum in a laminar flow hood using 
sterile technique. All extracts were stored in sterile polypropylene bottles at 2–8 °C until the time 
of analysis. The limulus amebocyte lysate (LAL) assay (Lonza, Basel, Switzerland) was 
performed on these extracts according to standard methods. Test results indicated all extracts to 
be free of endotoxin (lipopolysaccharide) with a sensitivity of 0.25 EU/mL. Extracts were tested 
for their effects on cultured macrophage-like cells in their original form, and also following 
precipitation in ethanol. To conduct ethanol precipitation, extracts were combined with ethanol 
(95%) at a ratio of 1 mL extract:1 mL ethanol (final 85% ethanol). The resulting mixtures were 
centrifuged, and the supernatant was retained and will hitherto be referred to as “precipitated 
extracts.” 
2.3. Analysis of extracts 
Reversed phase HPLC coupled with electrospray ionization mass spectrometry (ESI-MS) was 
employed to analyze the precipitated extracts, in accordance with previously published 
methods [32]. An HP1100 HPLC system (Agient, Palo Alto, CA, USA) with a narrow bore C18 
column (50 mm × 2.1 mm, 110 Å pore size, 3 μm particle size, Grace, Deerfield, IL, USA) was 
used. A precolumn filter (0.5 μm) (MacMod analytical, Chadds Ford, PA, USA) was employed 
in series with the column to filter out particulates. Binary gradient elution was employed at a 
flow rate of 0.2 mL/min with solvent A consisting of 1% acetic acid in nanopure water and 
solvent B consisting of HPLC grade acetonitrile (Pharmaco-AAPER, Shelbyville, KY, USA). 
Analyses were conducted separately for alkylamides and caffeic acid derivatives. For 
alkylamides, the solvent composition was as follows: t = 0–4 min, a constant composition of A–
B (90:10, v/v); for t = 4–15 min, a linear gradient from A–B (90:10, v/v) to A–B (60–40, v/v): 
for 15–30 min, a linear gradient from A–B (60:40, v/v) to A–B (40:60, v/v); for t = 30–35 min, a 
constant composition of A–B (90:10, v/v). For caffeic acid derivatives, the solvent composition 
was: t = 0–39 min, a linear gradient from A–B (90:10, v/v) to A–B (50–50, v/v); for t = 39–
43 min, a constant composition of A–B (90:10, v/v). An ion trap mass spectrometer with 
electrospray ionization (ESI) source (LCQ Advantage, Thermo Fisher, San Jose, CA, USA) was 
used. The mass spectrometer was operated over a scan range of 50–2000. Capillary, spray, and 
tube lens offset voltages were 3 V, 4.5 kV, and −60 V, respectively. Analyses of alkylamides 
were conducted in the positive ion mode while analyses of caffeic acid derivatives were 
conducted in the negative ion mode. 
2.4. Cells and media 
Murine RAW 264.7 macrophage-like cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA) and were cultured in Dulbecco's Modified Eagle's (DME) 
Medium with 4 mM l-glutamine, 4.5 g/L glucose, and 1.5 g/L sodium bicarbonate with 10% fetal 
calf serum (FCS). All media and supplements were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). FCS was obtained from Atlanta Biologicals (Atlanta, GA, USA). For production of 
cell culture supernatants, 1.5 × 105 cells/well were plated in 24 well tissue culture plates in 1 mL 
culture media. Cells were treated with extracts by diluting directly into cell media (6.7 μL of 
extracts prior to precipitation or 5.8 μL of precipitated extracts into a 1 mL well volume, for a 
final ethanol percentage of 0.5% in both cases). These amounts were selected to allow testing at 
a relevant concentration of alkylamide (see Table 1), while still keeping ethanol below a toxic 
level. Following treatment, supernatants were collected, centrifuged for 2 min at 8000 rpm to 
remove debris, aliquoted, and stored at −80 °C. 
2.5. Influenza A virus propagation 
Influenza A PR/8/34 (VR-1469) was purchased from the American Type Culture Collection 
(Manassas, VA, USA) and propagated in MDCK Cells (ATCC CCL-34). T-75 flasks of cells at 
90% confluency were inoculated with 0.01 MOI of virus in 2 mL of virus growth medium 
(VGM) made up of DMEM containing 0.2% bovine serum albumin (BSA), 25 mM Hepes 
buffer, 100 U/mL Penicillin, 100 μg/mL Streptomycin, and 2 μg/mL TPCK-treated Trypsin 
(LS003740, Worthington-Biochem, Lakewood, NJ, USA). Viral supernatants were harvested at 
36 to 48 h, centrifuged to remove cellular debris, and supplemented with BSA to a final 
concentration of 0.5%. Aliquots were frozen and stored at −80 °C. Titers of influenza A virus 
were determined by plaque assay using MDCK cells. Briefly, 200 μL of serially diluted virus in 
VGM was inoculated onto confluent MDCK cells in 24-well plates. After a 30 min absorption 
period, 0.8 mL of overlay was added (0.6% Tragacanth in VGM). After 48 h of incubation, the 
overlay was removed, the cells washed with cold PBS, fixed with cold acetone:methanol (1:1), 
and stained with crystal violet. 
2.6. ELISAs and arrays 
PGE2 and TNF-α ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA). The 
PGE2 kit is a competitive type immunoassay while the TNF-α kit is a direct capture assay. In 
each case, sample measurements were performed in duplicate and values were interpolated from 
standard curves. Optical density was determined using a PolarStar microplate reader (BMG 
Labtechnologies, Durham, NC, USA). For cytokine analysis, the RayBio Mouse Inflammation 
Antibody Array I was purchased from RayBiotech, Inc. (Norcross, GA, USA). According to 
manufacturer's instructions, the array membranes were incubated with blocking buffer followed 
by undiluted culture supernatants for 1.5 h. The membranes were washed and incubated with 
biotin-conjugated Abs for 1.5 h and HRP-conjugated streptavidin for 2 h. The membranes were 
next incubated in detection buffer and exposed to X-ray film. Finally, scans of the X-ray films 
were analyzed with Photoshop (Adobe) to determine spot density. 
2.7. Statistical analysis 
Significant differences between means were determined using unpaired Student's t-tests with 
95% confidence intervals, as calculated with PRISM® software (Graphpad Software, San Diego, 
CA, USA). Correlation between PGE2 and TNF-α concentration and levels of constituents 
(alkylamides, caftaric acid and cichoric acid) was evaluated using the Pearson test with SPPS 
software (IBM, Chicago, IL, USA). 
3. Results 
3.1. Effects of individual alkylamides on cytokine/chemokine secretion by RAW 264.7 
macrophage-like cells 
Fig. 1 shows a comparison of the structures of representative caffeic acid derivatives (1,2) and 
alkylamides (3–16) found in Echinacea species. Numbering is consistent with a previous 
publication [32], and can be cross referenced to the numbering system used by Bauer [31] as 
indicated in the figure caption. All of the compounds in Fig. 1 were detected in the E. 
purpurea extracts investigated except alkylamide 16 (undeca-2E-ene-8,10-diynoic acid 
isobutylamide), which is a constituent of E. angustifolia that was tested here for activity in its 
purified form. 
 
Fig. 1. Structures of caffeic acid derivatives (1 and 2) and alkylamides (3, 4, 5, 8, 11a, 11b, and 
15) present in Echinacea species. All of these compounds except 16 are common constituents 
of E. purpurea and were detected in the extracts prepared for this study. Compound 16 is a 
common constituent of Echinacea angustifolia and was not detected in the E. purpurea extracts. 
However, its anti-inflammatory activity alone was investigated ( Fig. 2). The numbering system 
used here is consistent with a previous publication [32]. For cross-referencing, alkylamides 3, 4, 5, 
11a, 11b, 15, and 16 in this paper correspond to alkylamides 1, 2, 3, 9, 8, 11, and 12, 
respectively, by the Bauer numbering system [31]. Alkylamide 8 in the figure was not included in 
the original Bauer publication. 
To evaluate the effects of alkylamide structure on inflammation, a set of four purified 
alkylamides was tested for their effects on the ability of RAW 264.7 macrophage-like cells to 
produce inflammatory products following infection with the influenza A virus strain PR/8/34. 
Included in this set were alkylamides 4 (undeca-2Z,4E-diene-8,10-diynoic acid isobutylamide), a 
mixture of isomers 11a and 11b (11a/b, dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide), 
15 (dodeca-2E,4E-dienoic acid isobutylamide), and 16 (undeca-2E-ene-8,10-diynoic acid 
isobutylamide). These alkylamides all contain the same isobutyl-substituted amide but vary in 
the length and or level of saturation of the alkyl chain (Fig. 1). The alkyl chains of akylamides 
15, 11a/b, 4, and 16 contain only single, two double, and two triple bonds, respectively. 
Initially, we investigated effects of these molecules on a key inflammatory mediator, TNF-
α [27], [28],[29] and [30]. When tested with control cells, none of the alkylamides induced significant 
production of TNF-α Fig. 2A, p < 0.05). In contrast, as shown in Fig. 2B, we found that all of the 
alkylamides tested suppressed production of TNF-α in a dose dependent fashion from RAW 
264.7 cells infected with influenza A strain PR/8/34 (Fig. 2B). Of the four alkylamides tested, 
alkylamide 4 and alkylamide 16 displayed the lowest levels of suppressive activity; alkylamides 
11a/b displayed an intermediate level of suppression, while alkylamide 15 displayed a 
particularly pronounced suppressive effect on production of TNF-α (Fig. 2B). It is possible that 
the strong suppressive activity of alkylamide 15 arises from the level of saturation in its alkyl 
chain; the isomeric mixture of alkylamides 11a/b, which was less active than alkylamide 15, 
possesses two extra double bonds. The di-acetylene bonds (two triple bonds) in alkylamides 4 
and 16 may be responsible for the low activity of these molecules. 
 
Fig. 2. Production of TNF-α from alkylamide treated RAW 264.7 macrophage-like cells. Cells 
alone (A) or cells infected with influenza strain A/PR8/34 (B) (moi = 5) were treated with the 
indicated concentrations of alkylamides and supernatants collected after 24 h. In panel B, 
infections were initiated 30 min prior to the addition of the alkylamides. Values shown are 
means +/− SEM from two independent experiments. Each supernatant was assayed in duplicate 
by ELISA. Asterisks indicate significant differences (p < 0.05, t-test) from untreated cells. The 
isomeric alkylamides 11a and 11b were tested as a mixture. 
To determine if the effects of these molecules are specific for TNF-α, or if they also affect 
production of other cytokines and chemokines, the two most potent alkylamides (15 and 11a/b) 
and a crude E. purpurea extract were tested for their effects on the production of multiple 
cytokines and chemokines using an antibody array. The array allows for the semi-quantitative 
identification of 40 different inflammatory proteins. Of these, 13 products were detected in 
supernatants from the control, alkylamide treated, raw extract treated (discussed later), and 
influenza A-infected RAW 264.7 cells ( Fig. 3). The other 27 products were not detected under 
any treatment condition. The control cells produced 10 products at low levels (G-CSF, GM-CSF, 
IL-4, IL12p70, IL-13, CXCL5/LIX, CCL3/MIP-1α, CCL5/RANTES, CCL1/TCA-3, and TIMP-
1), while two chemokines (CCL2/MCP-1 and CCL9/MIP-1γ) were produced at higher levels 
( Fig. 3A). Of the cytokines produced at low levels, alkylamide 15 caused significant 
enhancement of G-CSF and TNF-α (p < 0.05) while inhibiting production of GM-CSF 
(p < 0.05). The alkylamides 11a/b significantly inhibited production of G-CSF, GM-CSF, 
CCL5/LIX, CCL3/MIP-1α and TIMP (p < 0.05). Of the chemokines produced constitutively at 
high levels, neither alkylamide altered production of CCL2/MCP-1, while both alkylamides 
inhibited production of CCL3/MIP1-α (p < 0.05). Infection of RAW 264.7 cells with influenza A 
strain PR/8/34 caused increased expression of G-CSF, CCL2/MCP-1, CCL3/MIP-1α, 
CCL5/RANTES, and TNF-α ( Fig. 3B). For four of these molecules, G-CSF, CCL2/MCP-1, 
CCL3/MIP-1α, and TNF-α, both alkylamide 15 and alkylamides 11a/b exerted significant 
suppressive effects (p < 0.05). In addition, alkylamide 15 strongly inhibited production of 
CCL9/MIP-1γ and CCL5/RANTES while alkylamides 11a/b did not suppress production of 
these molecules. Taken together, these results show that alkylamides are capable of suppressing 
production of multiple cytokines and chemokines from influenza A-infected RAW 264.7 
macrophages, but there are clear differences in effectiveness for the different alkylamides. 
 
Fig. 3. Influence of alkylamides and a crude E. purpurea extract on the production of cytokines 
and chemokines by RAW 264.7 cells. Cells alone (A) or cells infected with influenza A strain 
PR/8/34 (B) were treated with media, the indicated alkylamides or extract #7 for 24 h. Infections 
were initiated 30 min prior to the addition of the alkylamides or the extract. Supernatants 
separate from those used in Fig. 2 were collected independently and a 1:4 dilution incubated with 
array membranes per manufacturer's instructions. Arrays were developed and spot intensity 
determined with Photoshop using digital images. Values shown are mean pixel intensities +/− SE 
from duplicate spots from a representative array. Asterisks indicate significant differences 
(p < 0.05, t-test) from untreated cells. The concentration of alkylamides was 25 μM and a 
dilution of 85% ethanol (precipitated) extract was used to produce a final concentration of 22 μm 
dodecatetraenoic acid isobutylamide (11a/b). 
Production of inflammatory lipids is also an important component of influenza A mediated 
pathology [27], therefore, the alkylamides were tested for their effects on the production of 
PGE2. The results were somewhat different than those for TNF-α. When tested on their own, 
three of the four alkylamides did not affect production of PGE2, whereas alkylamide 15 induced 
significant levels of PGE2 in culture supernatants (Fig. 4A). As shown in Fig. 4B, when tested 
with RAW 264.7 cells infected with strain PR/8/34, all the alkylamides inhibited production of 
PGE2 when used at a concentration of 50 μM. In general, however, significant suppression of 
PGE2 production was not seen with lower concentrations of the alkylamides. 
 
Fig. 4. Production of PGE2 from alkylamide treated RAW 264.7 macrophage-like cells. Cells 
alone (A) or cells infected with influenza strain A/PR8/34 (B) (moi = 5) were treated with the 
indicated concentrations of alkylamides and supernatants collected after 24 h. In panel B, 
infections were initiated 30 min prior to the addition of the alkylamides. Values shown are 
means +/− SEM from three independent experiments. Each supernatant was assayed in duplicate 
by ELISA. Asterisks indicate significant differences (p < 0.05, t-test) from untreated cells. The 
isomeric alkylamides 11a and 11b were tested as a mixture. 
3.2. Effects of complex E. purpurea extracts on production of cytokines, chemokines and 
PGE2by RAW 264.7 cells 
One of the goals of these studies was to determine the role that alkylamides play in the anti-
inflammatory activity of complex E. purpurea extracts. Toward this goal, seventeen crude 
extracts were prepared from dormant E. purpurea roots harvested from different locations across 
North Carolina ( Fig. 5). The extracts were tested for their ability to induce production of TNF-
α Fig. 6A), and inhibit influenza A-induced TNF-α production ( Fig. 6B). A number of the 
extracts did not affect levels of constitutive expression, while several actually significantly 
(p < 0.05) enhanced production of TNF-α, with levels rising more than twofold vs. control cells. 
As expected, infecting RAW 264.7 cells with influenza A strain PR/8/34 led to high levels of 
TNF-α (note the change in the scale of the y-axis) and again a range of effects was observed for 
the extracts ( Fig 6B). Several enhanced production up to 40%, several exerted no effect, while 
only extract 7 exerted a strong suppressive effect (p < 0.05). A weak but significant suppressive 
effect was noted in these experiments for extract 16, but this result was not confirmed in 
subsequent experiments (see below). In general, the extracts that stimulated production of TNF-α 
when used on their own also stimulated production from infected cells. Conversely, those 
extracts that displayed minimal activity when tested on their own also displayed minimal activity 
with infected cells. 
 
Fig. 5. Map of NC indicating the counties where the E. purpurea root samples were collected. 
 
 
Fig. 6. Production of TNF-α from crude E. purpurea extract treated RAW 264.7 macrophage-
like cells. Each ethanol extract was added to a 1 mL culture of either cells alone (A and C) or 
cells infected with influenza strain A/PR8/34 (B and D) (moi = 5) and supernatants collected 
after 24 h. In panels B and D, infections were initiated 30 min prior to the addition of the 
extracts. Panels A and B show results from treatments with 6.7 μL of 75% ethanol extracts while 
in panels C and D 5.8 μL of 85% ethanol (precipitated) extracts were added. Assay 
concentrations of dodecatetraenoic acid isobutylamide (11a/b) were in the range of 5–20 μM 
( Table 1). No extract (NE) control cultures included identical amounts of the appropriate ethanol 
concentrations. Values shown are means +/− SEM from two independent experiments. Each 
supernatant was assayed in duplicate by ELISA. Asterisks indicate significant differences 
(p < 0.05, t-test) from untreated cells. 
In recent literature, it has been reported that much of the ability of Echinacea extracts to 
stimulate production of inflammatory cytokines from macrophages may be caused by the 
presence of lipopolysaccharides or lipoproteins [18] and [19]. With this in mind, the extracts were 
precipitated with ethanol, which can remove these products and which increased the final ethanol 
concentration to 85%. A subset of these precipitated extracts was then tested for their effects on 
constitutive and influenza A-induced production of TNF-α. As shown in Fig. 6C, when a subset 
of the precipitated extracts were added to control cells, the magnitude of the stimulatory effect 
was reduced, however, several still produced significant (p < 0.05) increases in TNF-α 
production. A more pronounced effect was noted when influenza A-infected cells were treated 
with the precipitated extracts. None of these extracts induced significant increases in TNF-α 
production ( Fig. 6D) while two of the extracts (7 and 17) did significantly (p < 0.05) inhibit 
production of TNF-α. The suppressive effect noted in Fig. 6B for extract 16 was not confirmed 
in these experiments. It is possible that precipitation with ethanol diluted the extract, thereby 
reducing its all ready weak suppressive activity. 
As shown in Fig. 6D, one extract (7) strongly suppressed production of TNF-α in a manner 
similar to the purified alkylamides (Fig. 2); therefore, we investigated the effects of this extract 
on the production of additional cytokines and chemokines. As shown in Fig. 3A, with control 
cells, the extract significantly (p < 0.05) suppressed production of CCL3/MIP-1α, 
CCL5/RANTES, and TIMP-1. With infected cells, the extract enhanced production of IL-12p70 
while inhibiting production of TNF-α and IL-13 (p < 0.05). Unlike the purified alkylamides, 
however, the crude extract did not affect the influenza A-induced production of G-CSF, 
CCL2/MCP-1, CCL3/MIP-1α, CCL9/MIP-1γ, or CCL5/RANTES (Fig. 3B). 
The crude, 75% ethanol extracts were also tested for their effects on production of PGE2 (Fig. 7). 
With control cells, only one extract (12) caused significant stimulation of PGE2 production 
(Fig. 7A). In contrast, when tested with influenza A-infected cells, several of the extracts 
strongly enhanced PGE2 production while one (7) significantly inhibited production (Fig. 7B). 
To determine whether the stimulatory effects of the extracts could be attributed to bacterial 
products that may have been present, the extracts were retested after a single round of ethanol 
precipitation (Fig. 7C and D). With control cells, several of the precipitated extracts did cause 
significant (p < 0.05) but small increases in production of PGE2 (note the scale of the y-axis). 
More dramatically, when the precipitated extracts were tested with infected cells, none was 
found to enhance PGE2 production and several were found to significantly (p < 0.05) inhibit 
production. Again we noted that extract 7 produced the strongest suppressive effect. 
 
Fig. 7. Production of PGE2 by RAW 264.7 macrophage-like cells treated with crude E. 
purpurea extracts. Each ethanol extract was added to a culture of either cells alone (A and C) or 
cells infected with influenza strain A/PR8/34 (B and D). Panels A and B show results from 
treatments with 6.7 μL of 75% ethanol extracts while in panels C and D 5.8 μL of 85% ethanol 
(precipitated) extracts were added. Conditions were identical to those listed for Fig. 6, except 
that ELISA was conducted for PGE2 instead of TNF-α. Asterisks indicate significant differences 
(p < 0.05, t-test) from untreated cells. 
3.3. Alkylamide and caffeic acid derivative content of crude E. purpurea extracts and relation to 
activity 
Quantitative analysis of several major constituents (alkylamides 11a/b, caftaric acid and cichoric 
acid) was conducted to determine whether their concentration would correlate with the observed 
anti-inflammatory activity of the extracts. The assay concentration of alkylamide 11a/b in the 
precipitated extracts was observed to vary from 1.1 μg/mL to 5.4 μg/mL, a range of 5-fold 
(Table 1). However, the concentration of this constituent in the precipitated extracts was only 
moderately correlated with concentration of PGE2(r = −0.496, p = 0.04, Pearson) and TNF-α 
(r = −0.608, p = 0.03) in the cell media. Furthermore, there was no significant correlation 
(p < 0.05) between concentration of PGE2 or TNF-α in the cell media and concentration of 
caftaric or cichoric acid in the precipitated extracts (for caftaric acid and PGE2, r = −0.225, 
p = 0.4; for caftaric acid and TNF-α, r = −0.173, p = 0.6, for cichoric acid and PGE2, r = −0.025, 
p = 0.9; for cichoric acid and TNF-α, r = −0.133, p = 0.7). 
E. purpurea contains at least 16 different structurally diverse alkylamides [33]. For this study, 
only the most abundant of these, dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (11a/b) 
was quantified. It was of interest, however, to evaluate whether the presence of some of the other 
minor alkylamides would correlate with observed anti-inflammatory activity of the extracts. To 
accomplish this goal, correlation between HPLC peak area and concentration of PGE2 or TNF-α 
in the cell media was evaluated for each of the major alkylamides detected in the extract 
(compounds 3, 4, 5, 8, 11a/b, and 15 in Fig. 1). A moderate negative correlation was observed 
between the concentration of both PGE2 and TNF-α and the peak area of alkylamides 11a/b. This 
would be expected given the aforementioned correlation between concentration of alkylamide 
11a/b and levels of PGE2 and TNF-α. No correlation between PGE2 or TNF-α concentration and 
peak area for any of the other alkylamides (3, 4, 5, 8, 15) was observed. 
4. Discussion 
Influenza A is a virus that represents a continuous threat to human and animal health. Thousands 
of people die each year from the relatively mild strains of seasonal influenza A and, 
occasionally, highly pathogenic pandemic strains emerge as more serious threats. The virus' 
genetic information is in a continuous state of flux, making the continuous development of new 
vaccines a necessity. The genetic malleability of this virus also means that resistance to anti-viral 
agents develops with predictability and that constant development of new anti-viral compounds 
is also a necessity. Numerous investigations have shown that it is not the growth of the virus per 
se that causes many of the symptoms and pathology of the disease. Instead, many of the 
symptoms and pathology stem from the macrophage-dependent storm of inflammatory 
cytokines, chemokines, and inflammatory lipids that are triggered by the virus. Therefore, we 
investigated the effects of purified alkylamides and Echinacea extracts on the ability of influenza 
A strain PR/8/34 to induce the production of inflammatory products from RAW 264.7 
macrophage-like cells. 
All of the alkylamides tested suppressed production of TNF-α from virus infected cells. These 
data, in combination with previous results showing inhibition of TNF-α and other cytokines from 
LPS treated cells [23] and [24], suggest that alkylamides can mediate a ligand-independent effect on 
the production of TNF-α. Two of the alkylamides also displayed inhibitory activity against a 
number of additional cytokines and chemokines, including; G-CSF, GM-CSF, CCL2/MCP-1, 
CCL3/MIP-1α, CCL9/MIP-1γ and CCL5/RANTES. The mechanism underlying these effects is 
not known. A trypan blue exclusion assay failed to reveal evidence of alkylamide-induced cell 
death (data not shown) and, as shown in Fig. 3, the production of several cytokines and 
chemokines was unaffected by the alkylamides. Together, these findings argue against any broad 
toxic or inhibitory effect of the alkylamides on cellular metabolism. The finding that several 
cytokines and chemokines are produced equally in the absence or presence of the alkylamides 
also argues against the alkylamides exerting a strong suppressive effect on virus replication. The 
host response against influenza A is triggered by viral RNA interacting with a number of pattern 
recognition receptors including TLR-3, -7, -9,and RIG-I (reviewed in [34]) and strong inhibition 
of viral RNA production would likely cause broad, uniform inhibition of the host response. More 
likely, the effect of the alkylamides on production of TNF-α and other cytokines and chemokines 
stems from effects on specific transcription factors. An inhibitory effect on NF-κB might explain 
the effects of alkylamide 15 (dodeca-2E,4E-dienoic acid isobutylamide), for example, since 
expression of TNF-α [35], MCP-1 [35], and G-CSF[36] are dependent on this transcription factor. 
An alkylamide has also been implicated in activation of the orphan receptor PPARγ [37] which, 
along with the orphan receptors, is known to control the activity of many genes. On the other 
hand, arguing against a suppressive effect on transcription factors is the finding 
thatEchinacea extracts have been shown to enhance the production of multiple transcription 
factors [38]. It is also unclear if alkylamide binding to the cannabinoid type 2 (CB2) receptor is 
responsible for these effects. Previously, alkylamides 11a/b and 15 have both been shown to bind 
the CB2 receptor [24] and [26]. However, these alkylamides displayed distinct effects on cytokine 
and chemokine production, which suggests that distinct receptors may be involved. Clearly, 
additional experiments will be necessary to define the effects of the alkylamides on cytokine and 
chemokine expression. 
The results of our experiments also revealed inhibition of PGE2 production by the alkylamides. 
This effect was seen primarily at the 50 μM concentration, and the dilutions we tested did not 
produce readily interpretable dose response curves. In addition, we found that alkylamide 15 
stimulated production of PGE2when used with control cells but inhibited production of PGE2 by 
virus-exposed cells. It is possible, therefore, that the alkylamides are exerting multiple, complex 
effects on the biochemical pathways responsible for production of PGE2. Alkylamide 15, for 
example, might be stimulating constitutive, COX-1-dependent PGE2 production, while inhibiting 
influenza A-induced, COX-2-dependent production of PGE2. Stimulation of constitutive 
PGE2 production might arise from kinase activation and the phosphorylation of cPLA2, while 
inhibition of influenza A-dependent production of PGE2 might occur because expression of 
COX-2 is blocked. De novo transcription of COX-2 is necessary for PGE2 production in RAW 
264.7 cells[39]. Alternatively, the alkylamides could be mediating their effects on PGE2 through 
the induction of nitric oxide [40]. Nitric oxide has been shown to enhance COX-1-dependent, 
constitutive production of PGE2 and at the same time inhibit COX-2-dependent, inducible 
production of PGE2[41]. Again, additional experiments will be necessary to resolve the effects of 
the alkylamides on production of PGE2. 
In contrast to the effects of the purified alkylamides, the E. purpurea extracts tested did not 
generally display suppressive activities. We did observe a moderate correlation between 
alkylamide 11a/b concentration in the precipitated extracts and concentration of TNF-α 
(r = −0.608) and PGE2 in the cell media (r = −0.496). These values are indicative of a trend 
towards a suppressive effect of alkylamide 11a/b on secretion of TNF-α and PGE2 by the RAW 
264.7 cells. However, only extract 7 strongly inhibited production of both TNF-α and PGE2. This 
extract also partially suppressed the production of TNF-α and IL-13 from influenza infected 
cells. Why the extracts did not display the anti-inflammatory activity displayed by the purified 
alkylamides is not clear. One explanation for this observation would be that levels of 
alkylamides in the extracts were not sufficient to accomplish the effects seen with the isolated 
compounds. The concentrations of alkylamide 11a/b in the extracts (up to 5 μg/mL), however, 
were on the same order as the lowest concentration tested for this compound alone (6.25 μg/mL), 
and alkylamide 11a/b was still quite active at 6.25 μg/mL ( Fig. 2). Furthermore, the extracts 
were shown to contain a number of additional alkylamides ( Fig. 7); therefore, the total 
alkylamide concentration would certainly have been well within the active range. Finally, 
inhibitory activity was observed for several extracts that contained similar alkylamide levels to 
other inactive extracts (Fig. 7). All of these factors suggest that low alkylamide concentration 
could not account for the observed lack of activity of some of the extracts. 
Another possible explanation for the relative inactivity in the extracts is the presence of 
stimulatory molecules that work in opposition to the effects of inhibitory alkylamides. Several 
studies have shown thatEchinacea extracts can contain plant polysaccharides or 
glycoproteins [9] or products of (possibly endophytic) bacteria, such as lipopolysaccharide or 
lipoprotein [18] and [19], which stimulate macrophage activity. In agreement, our ethanol 
precipitation experiments (which should decrease the concentration of these stimulatory 
molecules) did reduce the stimulatory activity of the extracts used in these experiments. In fact, 
suppressive effects were revealed upon precipitation for some of some extracts that showed no 
suppressive activity prior to precipitation. We did not test whether ethanol precipitation can 
routinely and uniformly reduce the macrophage-stimulatory activity in Echinacea extracts or in 
plant extracts in general. 
We were able to rule out lipopolysaccharide (LPS) as the activating constituent in the extracts. 
As shown by the limulus amoebocyte lysate (LAL) assay, extracts contained less than 
0.25 EU/mL of LPS. This corresponds to an assay concentration of less than 0.1 pg/mL, 
approximately 10,000 times lower than the 1 ng/mL LPS concentration limit required to activate 
macrophages in our assay. Furthermore, addition of polymixin B, a compound that abrogates the 
effects of LPS [42], did not restore activity of the inactive extracts (data not shown). It is still 
possible that bacterial-derived lipoproteins, which are not detected with the LAL assay, are 
responsible for the stimulatory activity in the extracts. These, however, should also precipitate at 
high ethanol percentages. 
Alternatively, it is possible that the extracts did not act as did the purified alkylamides, because 
the mixture of alkylamides present in the extracts (Fig. 8) does not behave additively, or 
synergistically, but instead delivers contradictory signals to the macrophage. Several alkylamides 
have been shown to bind to the CB1and CB2 receptors [24] and [26], and Gertsch et al. [23] have 
reported that certain alkylamides can induce production of TNF-α mRNA (but not protein) in a 
CB2 receptor-dependent fashion. Alkylamides have also been shown to inhibit the LPS-induced 
expression of inflammatory cytokines in a CB2-independent manner[24], and to modulate several 
signal transduction and second messenger systems including cAMP, Ca++, and MAP kinases [23]. 
It is possible, therefore, that a complex mixture with multiple alkylamides generates 
contradictory signals into the cell, resulting in no net effect. 
 
Fig. 8. Chromatograms comparing alkylamide profiles in different E. purpurea root extract 
samples. Analysis was conducted via HPLC/ESI-MS in the positive ion mode using a previously 
published method [33]. Chromatograms are base peak chromatograms, which plot the intensity 
of the most abundant ion vs. time. Note the remarkable similarity in alkylamide profile between 
the samples, for example sample 2 (inactive) has an extremely similar profile to sample 7 (highly 
active). There was no correlation between peak area of any of the alkylamides and suppression of 
PGE2 secretion (evaluated by Pearson). 
Regardless of the reason, these data indicate that the effects of crude ethanolic E. 
purpurea extracts on the ability of influenza A to stimulate mediator production from 
macrophages in vitro can vary significantly depending on the plant material used in their 
preparation. In agreement with previous reports [20],[21] and [23], we show that some crude ethanolic 
extracts of E. purpurea do, indeed, possess anti-inflammatory activity in vitro, and that 
alkylamides alone possess this activity as well. However, our results suggest that the widely held 
belief that alkylamide rich ethanolic extracts of E. purpurea should have anti-inflammatory 
activity, while polysaccharide rich aqueous extracts should stimulate immune response, may be 
an oversimplification. With our in vitro model, we show that even some alkylamide-containing 
extracts with relatively high ethanol content (75%) can stimulate cytokine production by virus-
exposed macrophage-like cells in vitro, and that even increasing ethanol percentage to 85% does 
not restore anti-inflammatory activity for the stimulatory extracts. One important caveat when 
considering the relevance of these findings is that while the RAW 264.7 cell model is typically 
very predictive of in vivo effects [39], it does not take into account how the constituents of the 
extracts are absorbed or metabolized in the human body. If the extracts investigated in this study 
do contain stimulatory constituents that mask the anti-inflammatory activity of alkylamides, 
these same extracts could still display anti-inflammatory in vivo if the stimulatory molecules are 
not readily absorbed. 
Ultimately, given the findings from our laboratories and others that show anti-inflammatory 
activity of alkylamides, extracts with high alkylamide concentration would be expected to have 
anti-inflammatory activity. Further studies are needed to investigate the role of constituents other 
than alkylamides in the activity of E. purpurea extracts before the observed variability in the 
anti-inflammatory activity of these extracts in vitro can be explained. Such studies are relevant to 
the quality control of E. purpurea extracts used as dietary supplements or for in vivo studies. 
When the issue of other masking constituents present inE. purpurea extracts is resolved, the 
levels of alkylamides may indeed serve as a predictive biomarker for anti-inflammatory activity. 
Acknowledgments 
The authors would like to thank Gaia Herbs, Inc. for generously providing alkylamide standards 
used in this study and the many E. purpurea growers across North Carolina who 
provided Echinacea roots. Thanks are also owed to Kevin Spelman for technical assistance and 
to David Pasco for helpful advice. This research was supported by funding from the UNC 
Research Competitiveness Fund. 
References 
[1] U.S. nutrition industry overview. Nutr Bus J 2009;14:1–13. 
[2] Keller K. Legal requirements for the use of phytopharmaceutical drugs in the Federal 
Republic of Germany. J Ethnopharmacol 1991;32:225–9. 
[3] Grimm W, Muller H-H. A randomized controlled clinical trial of the effect of fluid extract of 
Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 
1999;106:138–43. 
[4] Melchart D, Linde K, Worku F, Sarkady L, Holzmann M, Jurcic K, et al. Results of five 
randomized studies on the immunomodulatory activity of preparations of Echinacea. J Altern 
Complement Med 1995;1:145–60. 
[5] Turner RB, Bauer R, Woelkart K, Hulsey TC, Gangemi JD. An evaluation of Echinacea 
angustifolia in an experimental rhinovirus infection. N Engl J Med 2005;353:341–8. 
[6] Turner RB, Riker DK, Gangmi JD. Ineffectiveness of Echinacea for prevention of 
experimental rhinovirus colds. Antimicorb Agents Chemother 2000;44:1708–9. 
[7] Matthias A, Addison RS, Agnew LL, Bone KM, Watson K, Lehmann RP. Comparison of 
Echinacea alkylamide pharmacokinetics between liquid and tablet preparations. Phytomedicine 
2007;14:587–90. 
[8] Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of Echinacea for the 
prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis 2007;7:473–80. 
[9] Bauer R. Echinacea: biological effects and active principles. In: Lawson LD, Bauer R, 
editors. Phytomedicines of Europe. Washington, DC: American Chemical Society; 1998. p. 140–
57. 
[10] Burger RA, Torres AR, ReedWP, Caldwell VD, Hughes BG. Echinacea-induced cytokine 
production by human macrophages. Int J Immunopharmacol 1997;19:371–9. 
[11] Pugh ND, Balacandran P, Lata H, Dayan FE, Joshi V, Bedir E, et al. Melanin: dietary 
mucosal immune modulator from Echinacea and other botanical supplements. Int 
Immunopharmacol 2005;5:637–47. 
[12] Rininger JA, Kickner S, Chigurupati P, McLean A, Franck Z. Immunopharmacological 
activity of Echinacea preparations following simulated digestion on murine macrophages and 
human peripheral blood mononuclear cells. J Leukoc Biol 2000;68:503–10. 
[13] Vohra S, Adams D, Hudson JB, Moore JA, Vimalanathan S, Sharma M, et al. Selection of 
natural health products for clinical trials: a preclinical template. Can J Physiol Pharmacol 
2009;87:371–8. 
[14] Luettig B, Steinmuller C, Gifford GE, Wagner H, Lohmann-Matthes ML. Macrophage 
activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea 
purpurea. J Natl Cancer Inst 1989;81:669–75. 
[15] Roesler J, Emmendorffer AC, Steinmuller C, Luettig B, Wagner H, LohmanMatthes ML. 
Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to test 
subjects mediates activation of the phagocyte system. Int Immunopharmacol 1991;13:931–41. 
[16] Steinmuller C, Roesler J, Grottrup E, Franke G, Wagner H, Lohmann-Matthes ML. 
Polysaccharides isolated from plant cell cultures of Echinacea purpurea enhance the resistance of 
immunosuppressed mice against systemic infections with Candida albicans and Listeria 
monocytogenes. Int J Immunopharmacol 1993;15:605–14. 
[17] Wagner H, Stuppner H, Puhlmann J, Schafer W, Zenk MH. Immunologically active 
polysaccharides of Echinacea purpurea cell cultures. Phytochemistry 1988;27:119–26. 
[18] Pugh ND, Tamta H, Balachandran P, Wu X, Howell J, Dayan FE, et al. The majority of in 
vitro macrophage activation exhibited by extracts of some immune enhancing botanicals is due 
to bacterial lipoproteins and lipopolysaccharides. Int Immunopharmacol 2008;8:1023–32. 
[19] Tamta H, Pugh ND, Balachandran P, Moraes R, Sumiyanto J, Pasco DS. Variability in in 
vitro macrophage activation by commercially diverse bulk Echinacea plant material is 
predominantly due to bacterial lipoproteins and lipopolysaccharides. J Agric Food Chem 
2008;56:10552–6. 
[20] Chen Y, Fu T, Tao T, Yang J, Chang Y, Wang M, et al. Macrophage activating effects of 
new alkamides from the roots of Echinacea species. J Nat Prod 2005;68:649–52. 
[21] Matthias A, Banbury L, Stevenson LM, Bone KM, Leach DN, Lehmann RP. Alkylamides 
from Echinacea modulate induced immune responses in macrophages. Immunol Investig 
2007;36:117–30. 
[22] Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple proinflammatory 
cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal 
extract. Antivir Res 2009;83:165–70. 
[23] Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNFalpha gene 
expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett 
2004;577:563–9. 
[24] Raduner S, Majewska A, Chen J-Z, Xie X-Q, Hamon J, Faller B, et al. Alkylamides from 
Echinacea are a new class of cannabinomimetics. J Biol Chem 2006:281. 
[25] Stevenson LM, Matthias A, Banbury L, Penman KG, Bone KM, Leach DL, et al. 
Modulation of macrophage immune responses by Echinacea. Molecules 2005;10:1279–85. 
[26] Woelkart K, Xu W, Pei Y, Makriyannis A, Picone R, Bauer R. The endocannabinoid system 
as a target for alkamides from Echinacea angustifolia roots. Planta Med 2005;71:701–5. 
[27] Kurokawa M, Imakita M, Kumeda CA, Shiraki K. Cascade of fever production in mice 
infected with influenza virus. J Med Virol 1996;50:152–8. 
[28] Langhans W. Anorexia of infection: current prospects. Nutrition 2000;16: 996–1005. 
[29] Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect 
Dis 2005;5:718–25. 
[30] Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein 
degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism 
for the increased degradation of muscle proteins during fever. N Engl J Med 1983;308:553–8. 
[31] Bauer R, Reminger P. TLC and HPLC analysis of alkamides in Echinacea drugs. Planta 
Med 1989;55:367–71. 
[32] Cech NB, Eleazer MS, Shoffner LT, Davis AC, Crosswhite MR, Mortenson AM. High 
performance liquid chromatography/electrospray ionization mass spectrometry for simultaneous 
analysis of alkylamides and caffeic acid derivatives from Echinacea purpurea extracts. J 
Chromatogr A 2006;1103:219–28. 
[33] Spelman K, Wetschler M, Cech NB. Comparison of alkylamide yield in ethanolic extracts 
prepared from fresh versus dry Echinacea purpurea utilizing HPLC-ESIMS. J Pharm Biomed 
Anal 2009;49:1141–9. 
[34] Ehrhardt C, Seyer R, Hrincius ER, Eierhoff T, Wolff T, Ludwig S. Interplay between 
influenza A virus and the innate immune signaling. Microbe Infect 2010;12:81–7. 
[35] Teferedegne B, Green M, Guo Z, Boss J. Mechanism of action of a distal NF-
kappabdependent enhancer. Mol Cell Biol 2006:26. 
[36] Nishizawa M, Nagata S. Regulatory elements responsible for inducible expression of the 
granulocyte colony-stimulating factor gene in macrophages. Mol Cell Biol 1990;10:2002–11. 
[37] Spelman K, Liams-Hauser K, Cech N, Taylor E, Smirnoff N, Wenner C. Role for PPARγ in 
IL-2 inhibition in t cells by Echinacea-derived undeca-2e-ene-8,10-diynoic acid isobutylamide. 
Int Immunopharmacol 2009;9:1260–4. 
[38] Sharma M, Arnason JT, Hudson JB. Echinacea extracts modulate the production of multiple 
transcription factors in uninfected cells and rhinovirus-infected cells. Phytother Res 
2006;20:1074–9. 
[39] Eads D, Hansen R, Oyegunwa A, Cecil C, Culver C, Scholle F, et al. Terameprocol, a 
methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and 
several key inflammatory cytokines and chemokines. J Inflamm 2009;6:2. 
[40] Lalone CA, Rizshsky L, Hammer KDP, Lankun W, Solco AKS, Yum M, et al. Endogenous 
levels of Echinacea alkylamides and ketones are important contributors to the inhibition of 
prostaglandin E2 and nitric oxide production in cultured macrophages. J Agric Food Chem 
2009;57:8820–30. 
[41] Clancy R, Varenika B, Huang W, Ballou L, Attur M, Amin AR, et al. Nitric oxide 
synthase/COX cross talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin 
production. J Immunol 2000;165:1582–7. 
[42] Morrison DC, Jacobs DM. Inhibition of lipopolysaccharide-initiated activation of serum 
complement by polymyxin B1. Infect Immun 1976;13:298–301. 
